Biosimilars business

Biocon Biologics Eyes $950 Million Bond Sale to Tackle $1.2 Billion Debt from Viatris Buy

Biocon Biologics aims to raise $950 million through overseas bonds, with the sale managed by Standard Chartered Bank and HSBC, according to sources familiar ...

Diksha Raj September 14, 2024